By Chris Wack
Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company.
Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research.
BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets.
Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 26, 2025 13:44 ET (18:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。